AIM AIM ImmunoTech Inc.: רווח נקי למניה ב-12 החודשים האחרונים

AIM ImmunoTech is exposed to geopolitical risks due to its reliance on foreign patents and the complexities of importing components. The annual net income per share trend visualizes these challenges, with the latest value recorded as -3.83. The development of RNA drugs is constrained by strict regulatory oversight and labor-intensive biochemical synthesis. Since the company is in the pre-revenue stage, its existence relies on equity issuance rather than sales.

This indicator reflects the actual efficiency of profit generation per share. By analyzing the current trailing 12-month EPS, an investor assesses the fundamental stability of capital. The metric is calculated by dividing the company's total annual net income by the total number of shares. For AIM ImmunoTech (AIM), this figure confirms the financial base supporting an elite staff of immunologists and the development of the R&D platform.